Daiichi Sankyo starts patient registration for new heart-condition drug in Europe
Japanese drug major Daiichi Sankyo (TYO: 4568) says it has enrolled the first patient for its trial to find out the impact of the Lixiana (edoxaban), its drug to treat heart disorders.
The company in a statement said under the program it will study the safety and efficacy parameters across 12 countries in Europe and collect data from up to 15,700 patients.
Juan-Carlos Jaramillo, head of market access and medical affairs, said: “Daiichi Sankyo is investing in the late phase program for edoxaban to answer customer’s question on the use of Lixiana.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze